Patents by Inventor David Caianiello

David Caianiello has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12234256
    Abstract: The disclosure describes compounds of Formula Ia, which in non-limiting aspects contain an asialoglycoprotein receptor (ASGPR) binding moiety and an anti-?1AR binding moiety. Compounds of Formula Ia are useful in preventing, treating, and/or ameliorating heart failure in a subject when administered in therapeutically effective amounts.
    Type: Grant
    Filed: March 8, 2023
    Date of Patent: February 25, 2025
    Assignee: YALE UNIVERSITY
    Inventors: David Caianiello, Edward DeRamon, David Spiegel
  • Patent number: 12128105
    Abstract: The disclosure describes compounds of Formula Ia, which in non-limiting aspects contain an asialoglycoprotein receptor (ASGPR) binding moiety and an anti-?1AR binding moiety. Compounds of Formula Ia are useful in preventing, treating, and/or ameliorating heart failure in a subject when administered in therapeutically effective amounts.
    Type: Grant
    Filed: March 8, 2023
    Date of Patent: October 29, 2024
    Assignee: Yale University
    Inventors: David Caianiello, Edward Deramon, David Spiegel
  • Publication number: 20240342293
    Abstract: The present disclosure provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In certain embodiments, the circulating protein mediates a disease and/or disorder in a subject, and treatment or management of the disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein in the subject. Thus, in certain embodiments, administration of a compound of the disclosure to the subject removes or reduces the circulation concentration of the circulating protein, thus treating, ameliorating, or preventing the disease and/or disorder.
    Type: Application
    Filed: October 9, 2020
    Publication date: October 17, 2024
    Inventors: David SPIEGEL, David CAIANIELLO, Emily BRANHAM
  • Patent number: 12083181
    Abstract: Described herein is a bi-functional compound for removing macrophage migration inhibitory factor (MIF) or immunoglobulin G (IgG). Further described herein is a pharmaceutical composition which comprise these bi-functional compounds. Further described herein is a method for treating disease states and/or conditions with the compounds or the composition. The disease states and/or conditions are mediated through MIF/IgG or where MIF/IgG is a contributing factor to the development and perpetuation of diseases and/or conditions, such as autoimmune diseases and cancer, among others.
    Type: Grant
    Filed: January 30, 2023
    Date of Patent: September 10, 2024
    Assignee: YALE UNIVERSITY
    Inventors: David Spiegel, David Caianiello
  • Publication number: 20240083859
    Abstract: The present invention is directed to bi-functional compounds which find use as pharmaceutical agents in the treatment of disease states and/or conditions which are mediated through macrophage migration inhibitory factor (MIF) or immunoglubin G (IgG). The present invention is also directed to pharmaceutical compositions which comprise these bi-functional compounds as well as methods for treating disease states and/or conditions which are mediated through MIF/IgG or where MIF/IgG is a contributing factor to the development and perpetuation of diseases and/or conditions, especially including autoimmune diseases and cancer, among others. The purpose of the present invention is to provide a molecular strategy to lower plasma MIF/IgG level in patients with autoimmune diseases or certain types of cancers.
    Type: Application
    Filed: August 8, 2023
    Publication date: March 14, 2024
    Inventors: David Spiegel, David CAIANIELLO
  • Publication number: 20240050578
    Abstract: Described herein is a bi-functional compound for removing macrophage migration inhibitory factor (MIF) or immunoglobulin G (IgG). Further described herein is a pharmaceutical composition which comprise these bi-functional compounds. Further described herein is a method for treating disease states and/or conditions with the compounds or the composition. The disease states and/or conditions are mediated through MIF/IgG or where MIF/IgG is a contributing factor to the development and perpetuation of diseases and/or conditions, such as autoimmune diseases and cancer, among others.
    Type: Application
    Filed: January 30, 2023
    Publication date: February 15, 2024
    Inventors: David Spiegel, David Caianiello
  • Publication number: 20230346951
    Abstract: The disclosure describes compounds of Formula Ia, which in non-limiting aspects contain an asialoglycoprotein receptor (ASGPR) binding moiety and an anti-?1AR binding moiety. Compounds of Formula Ia are useful in preventing, treating, and/or ameliorating heart failure in a subject when administered in therapeutically effective amounts.
    Type: Application
    Filed: March 8, 2023
    Publication date: November 2, 2023
    Inventors: David CAIANIELLO, Edward DERAMON, David SPIEGEL
  • Patent number: 11767301
    Abstract: The present invention is directed to bi-functional compounds which find use as pharmaceutical agents in the treatment of disease states and/or conditions which are mediated through macrophage migration inhibitory factor (MIF) or immunoglubin G (IgG). The present invention is also directed to pharmaceutical compositions which comprise these bi-functional compounds as well as methods for treating disease states and/or conditions which are mediated through MIF/IgG or where MIF/IgG is a contributing factor to the development and perpetuation of diseases and/or conditions, especially including autoimmune diseases and cancer, among others. The purpose of the present invention is to provide a molecular strategy to lower plasma MIF/IgG level in patients with autoimmune diseases or certain types of cancers.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: September 26, 2023
    Assignee: YALE UNIVERSITY
    Inventors: David Spiegel, David Caianiello
  • Publication number: 20230271994
    Abstract: The disclosure describes compounds of Formula Ia, which in non-limiting aspects contain an asialoglycoprotein receptor (ASGPR) binding moiety and an anti-?1AR binding moiety. Compounds of Formula Ia are useful in preventing, treating, and/or ameliorating heart failure in a subject when administered in therapeutically effective amounts.
    Type: Application
    Filed: March 8, 2023
    Publication date: August 31, 2023
    Inventors: David CAIANIELLO, Edward DERAMON, David SPIEGEL
  • Publication number: 20230233689
    Abstract: The present disclosure is directed to bifunctional small molecules which contain a circulating protein binding moiety (CPBM) linked through a linker group to a cellular receptor binding moiety (CRBM) which is a membrane receptor of degrading cell such as a hepatocyte or other degrading cell. In certain embodiments, the (CRBM) is a moiety which binds to asialoglycoprotein receptor (an asialoglycoprotein receptor binding moiety, or ASGPRBM) of a hepatocyte. In additional embodiments, the (CRBM) is a moiety which binds to a receptor of other cells which can degrade proteins, such as a LRP1, LDLR, Fc?RI, FcRN, Transferrin or Macrophage Scavenger receptor.
    Type: Application
    Filed: January 30, 2023
    Publication date: July 27, 2023
    Inventors: David Spiegel, David Caianiello, Mengwen Zhang
  • Publication number: 20230097887
    Abstract: Described herein is a bi-functional compound for removing macrophage migration inhibitory factor (MIF) or immunoglobin G (IgG). Further described herein is a pharmaceutical composition which comprise these bi-functional compounds. Further described herein is a method for treating disease states and/or conditions with the compounds or the composition. The disease states and/or conditions are mediated through MIF/IgG or where MIF/IgG is a contributing factor to the development and perpetuation of diseases and/or conditions, such as autoimmune diseases and cancer, among others.
    Type: Application
    Filed: March 15, 2022
    Publication date: March 30, 2023
    Inventors: David Spiegel, David Caianiello
  • Publication number: 20230087994
    Abstract: The present disclosure provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present disclosure provides bifunctional compounds that can be used to promote or enhance degradation of certain autoantibodies. In certain embodiments, treatment or management of a disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein or the autoantibody in the subject. Thus, in certain embodiments, administration of a compound of the disclosure to the subject removes or reduces the circulation concentration of the circulating protein or the autoantibody, thus treating, ameliorating, or preventing the disease and/or disorder. In certain embodiments, the circulating protein is TNF.
    Type: Application
    Filed: March 15, 2022
    Publication date: March 23, 2023
    Inventors: David Spiegel, David Caianiello, Jake Swartzel
  • Publication number: 20230090282
    Abstract: The present disclosure provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In certain embodiments, the circulating protein mediates a disease and/or disorder in a subject, and treatment or management of the disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein in the subject. Thus, in certain embodiments, administration of a compound of the disclosure to the subject removes or reduces the circulation concentration of the circulating protein, thus treating, ameliorating, or preventing the disease and/or disorder.
    Type: Application
    Filed: March 15, 2022
    Publication date: March 23, 2023
    Inventors: David SPIEGEL, David CAIANIELLO, Emily BRANHAM
  • Publication number: 20230083388
    Abstract: The present disclosure is directed to bifunctional small molecules which contain a circulating protein binding moiety (CPBM) linked through a linker group to a cellular receptor binding moiety (CRBM) which is a membrane receptor of degrading cell such as a hepatocyte or other degrading cell. In certain embodiments, the (CRBM) is a moiety which binds to asialoglycoprotein receptor (an asialoglycoprotein receptor binding moiety, or ASGPRBM) of a hepatocyte. In additional embodiments, the (CRBM) is a moiety which binds to a receptor of other cells which can degrade proteins, such as a LRP1, LDLR, Fc?RI, FcRN, Transferrin or Macrophage Scavenger receptor.
    Type: Application
    Filed: March 15, 2022
    Publication date: March 16, 2023
    Inventors: David Spiegel, David Caianiello, Mengwen Zhang
  • Publication number: 20210145974
    Abstract: The present invention is directed to bifunctional small molecules which contain a circulating protein binding moiety (CPBM) linked through a linker group to a cellular receptor binding moiety (CRBM) which is a membrane receptor of degrading cell such as a hepatocyte or other degrading cell. In embodiments, the (CRBM) is a moiety which binds to asialoglycoprotein receptor (an asialoglycoprotein receptor binding moiety, or ASGPRBM) of a hepatocyte. In additional embodiments, the (CRBM) is a moiety which binds to a receptor of other cells which can degrade proteins, such as a LRP1, LDLR, Fc?RI, FcRN, Transferrin or Macrophage Scavenger receptor. Pharmaceutical compositions based upon these bifunctional small molecules represent an additional aspect of the present invention. These compounds and/or compositions may be used to treat disease states and conditions by removing circulating proteins through degradation in the hepatocytes or macrophages of a patient or subject in need of therapy.
    Type: Application
    Filed: April 8, 2019
    Publication date: May 20, 2021
    Inventors: David Spiegel, David Caianiello, Mengwen Zhang
  • Publication number: 20210139436
    Abstract: The present invention is directed to bi-functional compounds which find use as pharmaceutical agents in the treatment of disease states and/or conditions which are mediated through macrophage migration inhibitory factor (MIF) or immunoglubin G (IgG). The present invention is also directed to pharmaceutical compositions which comprise these bi-functional compounds as well as methods for treating disease states and/or conditions which are mediated through MIF/IgG or where MIF/IgG is a contributing factor to the development and perpetuation of diseases and/or conditions, especially including autoimmune diseases and cancer, among others. The purpose of the present invention is to provide a molecular strategy to lower plasma MIF/IgG level in patients with autoimmune diseases or certain types of cancers.
    Type: Application
    Filed: April 8, 2019
    Publication date: May 13, 2021
    Inventors: David Spiegel, David Caianiello